You are here: Industry Insights > NICE

News List

NICE knocks-back Janssen's Imbruvica in mantle cell lymphoma pharmatimes
September 29, 2017
Janssen has received mixed news from the UK’s cost-effectiveness watchdog for its cancer drug Imbruvica (ibrutinib).
NICE nod for new Eylea indication pharmatimes
September 25, 2017
The National Institute for Health and Care Excellence (NICE) has issued a final positive recommendation for Bayer’s Eylea as a treatment for adults for the treatment of visual impairment due to myopic chorodial neovascularisation.
NICE recommends Bristol-Myers Squibb’s nivolumab for NSCLC patients on NHS pharmaceufical-technology
September 22, 2017
PD-L1 is involved in the body’s immune response to cancer and nivolumab demonstrates better effectiveness in patients who have more PD-L1 protein on their cancer cells.
NICE backs use of Opdivo for lung cancer pharmatimes
September 21, 2017
Bristol-Myers Squibb’s Opdivo is being recommended by the National Institute for Health and Care Excellence to treat a certain form of lung cancer on the NHS in England, via the Cancer Drugs Fund.
NICE rejects first-line use of Roche’s Gazyvaro pharmatimes
September 19, 2017
The National Institute for Health and Care Excellence has turned down first-line use of Roche’s Gazyvaro in patients with untreated advanced follicular lymphoma on the NHS in England and Wales.
Merck’s Erbitux backed by NICE for head and neck cancer pharmatimes
September 05, 2017
Merck’s Erbitux is being recommended for routine NHS use to treat recurrent or metastatic squamous cell cancer of the head and neck.
NICE turns down AZ’ Faslodex for breast cancer pharmatimes
September 04, 2017
It is looking unlikely that AstraZeneca’s breast cancer drug Faslodex will be routinely funded on the NHS to delay growth of a specific type of breast cancer, after cost regulators concluded that its benefit over existing therapies has not been shown at t
NICE rejects AstraZeneca's breast cancer drug Faslodex pharmafile
September 04, 2017
NICE has announced its decision to not recommend AstraZeneca’s breast cancer drug Faslodex (fulvestrant) in women who have oestrogen-receptor-positive
NICE flip-flops on Takeda's Adcetris—with restrictions fiercepharma
August 28, 2017
NICE issued negative draft guidance on Takeda's Adcetris last August.
NICE looks to toss Sanofi and Ipsen thyroid cancer drugs from Cancer Drugs Fund fiercepharma
August 24, 2017
NICE, which has been weeding out England's Cancer Drugs Fund, says it is not recommending that it pay for thyroid cancer drugs from Ipsen and Sanofi.

Previous page 1 2 3 4 5 6 7 8 9 10 ... 41 42 Next page